<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216007</url>
  </required_header>
  <id_info>
    <org_study_id>H10-01501</org_study_id>
    <nct_id>NCT01216007</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Investigate Plasma Bupivacaine Concentrations in Children Receiving Total Intravenous Anaesthesia and Caudal Analgesia</brief_title>
  <official_title>A Pilot Study to Investigate Plasma Bupivacaine Concentrations in Children Receiving Total Intravenous Anaesthesia and Caudal Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pilot study is to compare plasma [bupivacaine] between two groups of&#xD;
      paediatric patients under general anaesthesia who will all receive regional caudal&#xD;
      anaesthesia with bupivacaine: group 1 will receive TIVA and group 2 will receive a volatile&#xD;
      anaesthetic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      The investigators hypothesize that there will be a detectable difference in free plasma&#xD;
      [bupivacaine] between these two treatment groups, with lower free plasma [bupivacaine] in the&#xD;
      TIVA group.&#xD;
&#xD;
      Background:&#xD;
&#xD;
      Local anesthetics (LA) are frequently administered intra-operatively, in combination with&#xD;
      general anaesthesia, for pain management in children. Although highly effective in this&#xD;
      regard, LAs possess a narrow margin of safety. High plasma levels can cause toxicity in both&#xD;
      the central nervous system (CNS) and the cardiovascular system (CVS) and may result from&#xD;
      either the correct placement of an excessive dose or an inadvertent intravenous (IV)&#xD;
      injection of a correct dose.&#xD;
&#xD;
      Specific Objectives:&#xD;
&#xD;
      The objective of this pilot study is to compare plasma [bupivacaine] between two groups of&#xD;
      paediatric patients under general anaesthesia who will all receive regional caudal&#xD;
      anaesthesia with bupivacaine: group 1 will receive TIVA and group 2 will receive a volatile&#xD;
      anaesthetic.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Induction of anesthesia: The TIVA group will receive the BCCH standard regimen comprising&#xD;
      induction with propofol 5 mg/kg and remifentanil 2.5 mcg/kg, followed by maintenance infusion&#xD;
      of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Total cumulative&#xD;
      Intralipid® doses will be recorded at times of caudal injection and blood sampling. The&#xD;
      volatile anesthesia group will undergo inhalational induction with sevoflurane in oxygen,&#xD;
      followed by maintenance with a volatile agent of the anesthesiologist's choice. In both&#xD;
      groups, airway management will be at the discretion of the anesthesiologist. Standard minimum&#xD;
      monitoring will be applied. A caudal epidural will then be performed using a standard&#xD;
      technique.&#xD;
&#xD;
      Administration of caudal analgesia and whole blood sampling: A caudal dose of 1 ml/kg of&#xD;
      0.25% bupivacaine (2.5 mg/kg) with 1 in 200 000 epinephrine will be administered at time zero&#xD;
      (T0). Venous blood samples of 5 ml will be obtained from a second indwelling IV cannula 15&#xD;
      (T1) and 30 (T2) min after caudal injection. These will be collected into EDTA-containing&#xD;
      tubes by the PART research assistant and transferred to the BCCH pharmacy research technician&#xD;
      (blinded to anesthetic technique) for analysis. Blood samples will be immediately&#xD;
      centrifuged. The extracted plasma will be frozen at -850C. Total and free bupivacaine plasma&#xD;
      concentrations will be determined using high-pressure liquid chromatography (HPLC) and&#xD;
      ultrafiltration.&#xD;
&#xD;
      Data Analysis:&#xD;
&#xD;
      This pilot study will have two primary outcome measures, total and free plasma bupivacaine&#xD;
      concentrations. These data will be presented as mean (± SD) at T1 and T2. Normal distribution&#xD;
      will be tested by histogram plot. Between-group (TIVA vs. volatile anaesthesia) comparisons&#xD;
      of total and free plasma bupivacaine levels will be performed using appropriate analyses of&#xD;
      variance. This analysis will determine if there is a detectable difference in plasma&#xD;
      concentrations between the TIVA and volatile anaesthesia groups. These data will then be used&#xD;
      in a power calculation to determine necessary group sizes for a future randomized controlled&#xD;
      trial (RCT) study. Statistical analysis will be conducted using Analyse-It® (Analyse-It&#xD;
      Software, Leeds, UK) in consultation with a statistician (Clinical Research Statistical&#xD;
      Unit).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total and free plasma bupivacaine concentrations</measure>
    <description>5 mL blood sample will be obtained at 15 and 30min. Total and free plasma bupivacaine concentrations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>TIVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TIVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhalational</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhalational/volatile general anesthetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.</description>
    <arm_group_label>TIVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane</intervention_name>
    <description>In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.</description>
    <arm_group_label>Inhalational</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age 6 months - 5 years&#xD;
&#xD;
          -  ASA I-II&#xD;
&#xD;
          -  Undergoing elective day surgery for which combined general and caudal epidural&#xD;
             anaesthesia is indicated&#xD;
&#xD;
          -  Written parental/guardian informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Weight and body mass index &lt; 3rd or &gt; 97th percentile for age&#xD;
&#xD;
          -  Any contraindication to caudal injection&#xD;
&#xD;
          -  Renal, hepatic, neuromuscular or cardiac disease&#xD;
&#xD;
          -  Acute inflammatory process or infectious processes that provoke an acute phase&#xD;
             response, ongoing or resolved less than 2 weeks prior to recruitment day (such as&#xD;
             recent surgery, respiratory tract infection (including colds), urinary tract&#xD;
             infection, infectious or inflammatory gastroenteritis, otitis media, skin or wound&#xD;
             infection, cholecystitis, pancreatitis, hepatitis, meningitis) Chronic co-existing&#xD;
             inflammatory diseases (eg, inflammatory bowel disease, juvenile arthritis, cystic&#xD;
             fibrosis, autoimmune disease, connective tissue disease, chronic liver disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Whyte, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Children's Hospital, Department of Anesthesia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Simon Whyte</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Plasma</keyword>
  <keyword>bupivacaine</keyword>
  <keyword>concentration</keyword>
  <keyword>caudal</keyword>
  <keyword>epidural</keyword>
  <keyword>TIVA</keyword>
  <keyword>Inhalational</keyword>
  <keyword>anesthesia</keyword>
  <keyword>Caudal epidural</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

